文献速递免疫规划妇幼与学校卫生传染病防控与疫情报告

2022年印度孕妇风疹免疫状况与先天性风疹综合征(CRS)负担

Rubella immunity among pregnant women and the burden of congenital rubella syndrome (CRS) in India, 2022.
PubMed 文献 · Vaccine · 2024-07-02

2022年8-10月在印度13个哨点对孕妇开展风疹IgG血清学调查,血清阳性率为85.2%(95%CI:84.0,86.2)。在参与两轮调查的10个哨点中,2017/2019年合并血清阳性率为83.5%(95%CI:82.1,84.8),2022年为85.1%(95%CI:83.8,86.3),两期无差异。基于感染力模型估计,2017/2019年CRS年发病率为218.3/10万活产(95%CI:209.7,226.5),每年47120例;麻风疹疫苗运动后CRS发病率降至5.3/10万活产(95%CI:0,21.2),每年1141例。

要点

  • 2022年印度孕妇风疹血清阳性率为85.2%(95%CI:84.0,86.2)。
  • 10个哨点两期血清阳性率无差异:2017/2019年83.5% vs 2022年85.1%。
  • CRS年发病率从2017/2019年的218.3/10万活产降至疫苗运动后的5.3/10万活产。

核心结论

  • 全国麻风疹疫苗接种运动后印度CRS发病率大幅下降。
  • 约15%育龄妇女缺乏风疹免疫而易感。
  • 国家免疫规划未为育龄妇女提供常规风疹疫苗接种机会,须保持儿童风疹疫苗高接种率以防止育龄易感妇女暴露于风疹病毒。

研究设计与样本

  • 2022年8-10月在印度13个哨点对孕妇开展横断面血清学调查,估算风疹IgG抗体血清阳性率。
  • 利用2017/2019年(疫苗运动前及期间)和2022年(疫苗运动后)血清学调查的年龄别血清阳性率数据,建立感染力模型估算CRS发病率和负担。

主要发现

  • 2022年风疹血清阳性率为85.2%(95%CI:84.0,86.2)。
  • 参与两轮调查的10个哨点中,2017/2019年合并血清阳性率为83.5%(95%CI:82.1,84.8),2022年为85.1%(95%CI:83.8,86.3),两期无差异。
  • 2017/2019年印度CRS年发病率为218.3/10万活产(95%CI:209.7,226.5),每年47120例(95%CI:45260,48875)。
  • 麻风疹疫苗接种运动后CRS发病率降至5.3/10万活产(95%CI:0,21.2),每年1141例(95%CI:0,4569)。

临床怎么用

  • 作者认为,由于国家免疫规划未为育龄妇女提供常规风疹疫苗接种机会,须保持儿童风疹疫苗高接种率以防止育龄易感妇女暴露于风疹病毒。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: India aims to eliminate rubella and congenital rubella syndrome (CRS) by 2023. We conducted serosurveys among pregnant women to monitor the trend of rubella immunity and estimate the CRS burden in India following a nationwide measles and rubella vaccination campaign. METHODS: We surveyed pregnant women at 13 sentinel sites across India from Aug to Oct 2022 to estimate seroprevalence of rubella IgG antibodies. Using age-specific seroprevalence data from serosurveys conducted during 2017/2019 (prior to and during the vaccination campaign) and 2022 surveys (after the vaccination campaign), we developed force of infection (FOI) models and estimated incidence and burden of CRS. RESULTS: In 2022, rubella seroprevalence was 85.2% (95% CI: 84.0, 86.2). Among 10 sites which participated in both rounds of serosurveys, the seroprevalence was not different between the two periods (pooled prevalence during 2017/2019: 83.5%, 95% CI: 82.1, 84.8; prevalence during 2022: 85.1%, 95% CI: 83.8, 86.3). The estimated annual incidence of CRS during 2017/2019 in India was 218.3 (95% CI: 209.7, 226.5) per 100, 000 livebirths, resulting in 47,120 (95% CI: 45,260, 48,875) cases of CRS every year. After measles-rubella (MR) vaccination campaign, the estimated incidence of CRS declined to 5.3 (95% CI: 0, 21.2) per 100,000 livebirths, resulting in 1141 (95% CI: 0, 4,569) cases of CRS during the post MR-vaccination campaign period. CONCLUSION: The incidence of CRS in India has substantially decreased following the nationwide MR vaccination campaign. About 15% of women in childbearing age in India lack immunity to rubella and hence susceptible to rubella infection. Since there are no routine rubella vaccination opportunities for this age group under the national immunization program, it is imperative to maintain high rates of rubella vaccination among children to prevent rubella virus exposure among women of childbearing age susceptible for rubella.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Shanmugasundaram D, Viswanathan R, Winter AK, et al. Rubella immunity among pregnant women and the burden of congenital rubella syndrome (CRS) in India, 2022. Vaccine. 2024. PMID: 38960788. doi:10.1016/j.vaccine.2024.06.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。